Skip to main content
PharmaResources (Shanghai) Co., Ltd. logo

PharmaResources (Shanghai) Co., Ltd. — Investor Relations & Filings

Ticker · 301230 ISIN · CNE1000065Q9 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 458 across all filing types
Latest filing 2023-04-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301230

About PharmaResources (Shanghai) Co., Ltd.

https://www.pharmaresources.cn

PharmaResources (Shanghai) Co., Ltd. is a comprehensive Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) specializing in small molecule drug discovery and development. The company provides an integrated platform of services including medicinal chemistry, custom synthesis, process research and development, and analytical chemistry. PharmaResources supports global pharmaceutical and biotechnology partners through the entire drug development lifecycle, from initial lead optimization to the commercial-scale manufacturing of advanced intermediates and Active Pharmaceutical Ingredients (APIs). With a focus on technical innovation and quality management, the firm utilizes advanced synthetic methodologies and process engineering to accelerate drug candidates toward clinical trials and market approval.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于上海泓博智源医药股份有限公司使用部分超募资金投资建设项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the use of excess raised funds by Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It includes extensive information about the raised funds, their usage plans, project details, approvals by the board, supervisory board, independent directors, and the sponsor's verification opinion. The document references regulatory guidelines and approvals related to the use of raised funds and investment projects. It is not a full annual or interim financial report, nor is it a simple announcement or certification. The content focuses on the verification and approval of the use of excess raised funds for investment projects, which aligns with the category of Capital/Financing Update (CAP), as it deals with fundraising and capital usage updates.
2023-04-21 Chinese
第三届董事会第七次会议相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a formal opinion from independent directors regarding the reappointment of an external audit firm for the 2023 fiscal year. It references compliance with stock exchange listing rules and internal company governance documents. The content focuses on the approval of audit-related matters to be presented at a board meeting. The document is short (711 characters) and does not contain financial statements or detailed audit results, but rather a pre-approval opinion. This fits best under Board/Management Information (MANG) as it relates to board meeting matters and approvals, not a full audit report or annual report. It is not a report publication announcement or regulatory filing since it contains substantive board-related content.
2023-04-21 Chinese
关于募投项目延期的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. regarding the postponement of a fundraising investment project. It details the approval by the board and supervisory committee, the reasons for the delay, the impact on the company, and includes opinions from independent directors and the sponsoring institution. The document is relatively short (3271 characters) and focuses on the update about the fundraising project timeline without containing comprehensive financial statements or detailed financial performance data. It is not a full annual or interim report, nor is it a certification or a voting result announcement. It is a specific update on capital use and project progress related to fundraising. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-04-21 Chinese
内部审计制度
Governance Information Classification · 95% confidence The document is titled '内部审计制度' which translates to 'Internal Audit System' or 'Internal Audit Policy' of Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. It details the internal audit framework, responsibilities, authorities, procedures, and reporting within the company. The content is a policy or governance document about internal audit practices rather than an audit report itself. It does not contain financial statements, audit opinions, or results of external audits. It is a governance-related document describing internal control and audit processes, roles, and responsibilities. Therefore, it fits best under Governance Information (CGR) which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is sufficient and it is not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2023-04-21 Chinese
中信证券股份有限公司关于上海泓博智源医药股份有限公司2022年度募集资金存放与使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度募集资金存放与使用情况专项核查报告" which translates to "2022 Annual Special Verification Report on the Deposit and Use of Raised Funds". It is issued by the sponsor (中信证券股份有限公司) for the company 上海泓博智源医药股份有限公司. The content details the amount of funds raised in the IPO, their deposit, management, usage, and compliance with regulatory requirements. It includes verification by an accounting firm and the sponsor's review and opinion. The document is a specialized report focusing on the use and management of funds raised from the IPO, not a full annual report or earnings release. It is a standalone audit/verification report related to the use of raised capital, consistent with the definition of an Audit Report / Information (AR). The document length is sufficient and contains substantive financial and compliance information, not merely an announcement or certification. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2022
2023-04-21 Chinese
2022年度监事会工作报告
Board/Management Information Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report". It details the supervisory board's activities, meetings, opinions on company operations, financial oversight, internal controls, and compliance with regulations during the 2022 fiscal year. The content focuses on the supervisory board's oversight and governance functions rather than presenting full financial statements or audit opinions alone. The document length is 2617 characters, which is relatively short and more consistent with a report or summary rather than a full annual report or audit report. It is not an announcement of a report but the report itself. Given the focus on supervisory board work and oversight, this fits best under the category of Board/Management Information (MANG), which includes announcements or reports related to board or senior management activities. It is not an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS) because it is a specific supervisory board work report. Therefore, the classification is MANG with high confidence.
2023-04-21 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.